• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CTXR

    Citius Pharmaceuticals Inc.

    Subscribe to $CTXR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products targeting medical needs with a focus on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing four proprietary products, including Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

    IPO Year:

    Exchange: NASDAQ

    Website: citiuspharma.com

    Peers

    $MRNS
    $RLMD
    $TTNP
    $AMPE

    Recent Analyst Ratings for Citius Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    12/30/2024$9.00Hold → Buy
    D. Boral Capital
    1/18/2022$4.00 → $6.00Buy
    HC Wainwright & Co.
    11/30/2021$4.00Buy
    Maxim Group
    See more ratings

    Citius Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Webb Carol

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:31 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Dutia Suren G

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:22 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vice Chairman Holubiak Myron Z

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:18 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Smith Robert Joseph

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:29 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Czuczman Myron

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:23 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Bartushak Jaime

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:27 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Mazur Leonard L

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:25 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mcgrath Dennis M

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:20 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Holuka Eugene Myron

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:16 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vice Chairman Holubiak Myron Z

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      9/27/24 5:27:04 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Citius Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Citius Pharmaceuticals Inc.

      SC 13D/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      11/27/24 4:05:31 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Citius Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      5/8/24 2:22:56 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Citius Pharmaceuticals Inc.

      SC 13G - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      1/31/24 2:08:26 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Citius Pharmaceuticals Inc.

      SC 13G - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      7/8/22 4:56:58 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Citius Pharmaceuticals Inc. (Amendment)

      SC 13D/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      2/18/22 4:31:05 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Citius Pharmaceuticals Inc. (Amendment)

      SC 13D/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      2/18/22 4:30:19 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      2/16/21 3:00:26 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Citius Pharmaceuticals Inc. SEC Filings

    See more
    • SEC Form DEFA14A filed by Citius Pharmaceuticals Inc.

      DEFA14A - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      4/28/25 7:32:02 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Citius Pharmaceuticals Inc.

      DEF 14A - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      4/28/25 7:30:15 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Citius Pharmaceuticals Inc.

      PRE 14A - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      4/18/25 4:07:02 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      4/18/25 4:05:37 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      4/3/25 4:15:08 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      4/2/25 4:05:37 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Citius Pharmaceuticals Inc.

      424B5 - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      4/2/25 7:27:15 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      3/10/25 4:30:09 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      2/14/25 4:47:46 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Citius Pharmaceuticals Inc.

      10-Q - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      2/14/25 4:30:31 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Citius Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citius Pharmaceuticals upgraded by D. Boral Capital with a new price target

      D. Boral Capital upgraded Citius Pharmaceuticals from Hold to Buy and set a new price target of $9.00

      12/30/24 7:26:29 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Citius Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Citius Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously

      1/18/22 10:01:19 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Citius Pharmaceuticals with a new price target

      Maxim Group initiated coverage of Citius Pharmaceuticals with a rating of Buy and set a new price target of $4.00

      11/30/21 8:45:24 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright resumed coverage on Citius Pharmaceuticals

      HC Wainwright resumed coverage of Citius Pharmaceuticals with a rating of Buy

      3/2/21 5:46:31 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dawson James resumed coverage on Citius Pharmaceuticals with a new price target

      Dawson James resumed coverage of Citius Pharmaceuticals with a rating of Buy and set a new price target of $6.00

      2/25/21 4:08:33 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Citius Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

      Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma

      12/27/24 5:00:00 PM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

      Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team. A question and answer period will follow management's discussion. Conference Call Details: Date: Tuesday, August 13, 2024 Time: 8:30 a.m. Eastern Time Dial In: 1-888-243-4451 (U.S. toll free) 1-412-542-4135 (international) Webcast: Register for the webcast here. A replay will

      8/12/24 8:00:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

      Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET CRANFORD, N.J., May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team to discuss the results of the Phase 3 Trial and the clinical need for Mino-Lok in patients with catheter-related blood

      5/29/24 8:30:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update

      $41.7 million in cash and cash equivalents as of September 30, 2022; extends runway through December 2023 Mino-Lok® Phase 3 trial closer to completion with 169 patients recruited, 72 failure events and 17 patients in active treatment or pending data review I/ONTAK BLA accepted for filing by the FDA; updated PDUFA target action date is July 28, 2023 Halo-Lido Phase 2b trial progressed; data readout expected 2H 2023 Multiple value-driving catalysts anticipated in 2023, including a potential drug approval and two trial completions CRANFORD, N.J., Dec. 22, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated

      12/22/22 4:30:00 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

      CRANFORD, N.J., Sept. 7, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR) today announced that it has entered into a definitive agreement with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, "Dr. Reddy's") (NYSE:RDY) to acquire its exclusive license of E7777 (denileukin diftitox), a late-stage oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma. E7777, an engineered IL-2-diphtheria toxin fusion protein, is an improved formulation of oncology agent, ONTAK®, which was previously approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with persist

      9/7/21 7:30:00 AM ET
      $CTXR
      $RDY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Citius Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls

      CRANFORD, N.J., Nov. 5, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced the appointment of pharmaceutical industry veteran Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls (CMC). Mr. Creighton will be responsible for the global strategic regulatory and manufacturing development plans for Citius's five pipeline programs. "With two late P

      11/5/21 9:15:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations

      CRANFORD, N.J., May 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR) today announced that Ilanit Allen has been appointed Vice President of Corporate Communications and Investor Relations, effective immediately.  In this newly created role, Ms. Allen will spearhead financial communication and investor activities, reporting to Myron Holubiak, President and Chief Executive Officer of Citius. "We are thrilled to welcome Ilanit to the Citius team as we advance our pipeline of first-in-class critical care products," stated Mr. Holubiak. "I am confident that Ilanit's extensive communications and investor relations experience, coupled with her financia

      5/17/21 12:30:00 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Citius Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

      CEO Leonard Mazur to present on Thursday, June 5, 2025, at 3:10 pm ET CRANFORD, N.J., May 5, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) and its oncology subsidiary, Citius Oncology, Inc. (NASDAQ:CTOR), today announced that Leonard Mazur, Chairman and Chief Executive Officer of both companies, will present at the Jefferies Global Healthcare Conference, taking place June 3 – June 5, 2025 in New York City. Conference Details:                Presentation: 3:10 pm ET on Thursday, June 5, 2025* Location: New York City Webcast: A live and archived webcast of the presentation will be available here.    A replay will be available for a limited time following the presentation on

      5/5/25 8:37:00 AM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

      CRANFORD, N.J., April 1, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into a definitive agreement for the purchase of 1,739,131 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.15 per share (or pre-funded warrant in lieu thereof). The closing of the offering is expected to occur on or about April 2, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the of

      4/1/25 9:00:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

      CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2024. Fiscal First Quarter 2025 Business Highlights and Subsequent Developments Substantially advanced operational readiness for commercial launch of LYMPHIR in the first half of 2025;Secured a new permanent J-code, J9161, (Injection, denileukin diftitox-cxdl, for intravenous use, 1 microgram) for LYMPHIR™, assigned by the Centers for Medicare & Medicaid Serv

      2/14/25 4:30:00 PM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

      Permanent J-Code (J9161) expected to be effective April 1, 2025 LYMPHIR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. CRANFORD, N.J., Feb. 6, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today announced that LYMPHIR™ (denileukin diftitox-cxdl) has been assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J9161) by the Centers for Medicare & Medicaid

      2/6/25 8:55:00 AM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

      CRANFORD, N.J., Jan. 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 743,496 shares of its common stock and accompanying warrants to purchase up to an aggregate of 743,496 shares of its common stock, at a purchase price of $4.035 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $3.91 per share, will be exercisable immedia

      1/8/25 8:00:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

      CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR) and its oncology-focused subsidiary, Citius Oncology (NASDAQ:CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Management is focused on making LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half of 2025. "Since LYMPHIR's approval in August 2024, we have worked diligently toward supporting its successful launch. We are making significant progress to f

      1/7/25 8:08:00 AM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

      CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (NASDAQ:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value. The engagement of Jefferies underscores Citius Oncology's commitment to exploring all avenues for enhancing its strategic positioning and advancing its mission to improve patient outcomes in oncology

      1/6/25 7:50:00 AM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

      Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma

      12/27/24 5:00:00 PM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

      CRANFORD, N.J., Nov. 25, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the Company held a constructive in-person Type C meeting with the U.S. Food and Drug Administration (FDA). The meeting followed successful completion of the Company's pivotal Phase 3 clinical trial of Mino-Lok®, a novel catheter lock solution designed to salvage central venous catheters in patients suffering from central line-associated bloodstream infections (CLABSI) or catheter-related bloodstream infections (CRBSI). The primar

      11/25/24 8:03:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

      CRANFORD, N.J., Nov. 22, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR) announced today that it will be executing a reverse stock split of its common stock, par value $0.001 per share, at a ratio of 1-for-25 ("Reverse Stock Split"). Pursuant to the laws of the State of Nevada and subject to prior approval by the Company's Board of Directors, Citius Pharma was not required to obtain shareholder approval to effectuate the Reverse Stock Split. The Reverse Stock Split will become effective at 5:00 pm Eastern Time on November 25, 2024. The Company's common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis beginning

      11/22/24 9:00:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care